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Teaser This study can inform different stakeholders on how to conduct, assess, and use patient
preference studies and on when to include patient preference studies in development plans.
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Industry, regulators, health technology assessment (HTA) bodies, and
payers are exploring the use of patient preferences in their decision-
making processes. In general, experience in conducting and assessing
patient preference studies is limited. Here, we performed a systematic
literature search and review to identify factors and situations influencing
the value of patient preference studies, as well as applications throughout
the medical product lifecyle. Factors and situations identified in 113
publications related to the organization, design, and conduct of studies,
and to communication and use of results. Although current use of patient
preferences is limited, we identified possible applications in discovery,
clinical development, marketing authorization, HTA, and postmarketing
phases.
Introduction
The importance of incorporating patient needs and perspectives into decision making through-
out the lifecycles of drugs and medical devices, for the purpose of this study collectively called the
medical product lifecycle (MPLC), is receiving increasing recognition [1–4]. Recognition of the
value of patients’ perspectives has led to a shift in drug development and assessments, from only
looking at clinical outcomes to taking into account the judgements of patients on how these
outcomes affect their lives. This shift originates from the notion that patients should be at the
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Attribute feature of the product under investigation (e.g.
price) [126]
External validity the degree to which it is warranted to
generalize results to other contexts
Internal validity the extent to which a causal conclusion
based on a study is warranted. Such warrant is constituted by
the extent to which a study minimizes systemic error (or
‘bias’)
Level value of the attribute (e.g., US$10) [126]
Patient preferences (patient preference information)
qualitative or quantitative assessments of the relative
desirability or acceptability to patients of specified
alternatives or choices among outcomes or other attributes
that differ among alternative health interventions [4]
Preference elicitation method quantitative methods
collecting quantifiable data that can be reported through
statistical inferences or analysis
Preference exploration method qualitative methods that
collect descriptive data through participant or phenomenon
observation, examining the subjective experiences and
decisions made by participants
Preference-sensitive situation preference-sensitive
decisions are those in which there are multiple diagnostic or
treatment options, and the decision which option to pursue
depends upon the particular preferences of the decision-
maker [3]center of the MPLC, because they are the ones not only gaining the
benefits, but also being exposed to the risks [5].
One option to better understand the patient perspective is
through exploring and eliciting patient preferences (see Glos-
sary). The US Food and Drug Administration (FDA) refers to patient
preferences by defining patient preference information as
‘qualitative or quantitative assessments of the relative desirability
or acceptability to patients of specified alternatives or choices
among outcomes or other attributes that differ among alterna-
tive health interventions’ [4]. Patient preferences can be obtained
through the use of different exploration (qualitative) and elicita-
tion (quantitative) methods [6]. Preference exploration meth-
ods can be defined as qualitative methods that collect descriptive
data through participant or phenomenon observation, and exam-
ining the subjective experiences and decisions made by partici-
pants. Examples of preference exploration methods include semi-
structured interviews and focus groups. Preference elicitation
methods can be defined as quantitative methods collecting
quantifiable data that can be reported through statistical infer-
ences or analysis. Examples of preference elicitation methods
include discrete choice experiments (DCE), analytical hierarchy
process (AHP), and standard gamble. Although methods can be
classified as exploration or elicitation methods, they can also be
classified as structured-weighting, health-state utility, stated-pref-
erence, or revealed-preference methods, as described in the Medi-
cal Device Innovation Consortium (MDIC) Patient Centered
Benefit-Risk Project report [3,7].
Stakeholders, including the pharmaceutical and medical device
industry, regulatory authorities, HTA bodies, payers, clinicians,
academia, and patient organizations, generally agree that there is
value in using patient preferences to inform assessments and58 www.drugdiscoverytoday.comdecision making [1,3,4,8–13]. In addition, patients themselves
have expressed interest in decision-making processes [14]. Patient
preferences are found to provide additional information on medi-
cal products, such as insights into the relative importance of
clinical outcomes and safety issues, and to help in transparent
communication regarding the incorporation of patient views in
regulatory decision making [1,3,15,16]. Moreover, they can lead to
more relevant, well-informed, transparent, publically trusted, and
patient-centric decisions [3,13,17,18]. In HTA specifically, patient
preferences are believed to provide a health condition perspective
and to improve the usefulness, appropriateness, and acceptability
of the assessments [2,8,19,20]. Also, consideration of patient pre-
ferences in clinical trial design can lead to a lower burden for
patients participating in the trial, and could result in improved
recruitment, retention, and compliance of patients. Moreover, it
could lead to more real-world clinical outcomes if preferences of
patients are considered during the establishment of treatment
arms [4,21–25].
European and US industry, regulators, HTA bodies, and payers
are currently exploring the use of patient preferences in their
processes and decision making. However, in general, these stake-
holders have limited experience in conducting and assessing these
studies. Moreover, they are generally not familiar with factors
influencing the value of these studies, the situations in which
these studies are most valuable, and possible applications of
patient preferences in their processes and decision making [26–
28].
By performing a systematic literature search and review (see SP.I
in the Supplemental information online) focused on the current
measurement and use of patient preferences in Europe and the US,
here we provide an overview of factors and situations that influ-
ence the value of patient preference studies. We also investigated
applications of patient preferences in assessments and decision
making along the MPLC.
Overview of applications of patient preferences along
the medical product lifecycle
A total of 113 publications were included in the literature review
(see SP.II in the Supplemental information online). Before we
explore the factors and situations that influence the value of
patient preference studies in assessments and decision making
along the MPLC, first we give a short overview of how patient
preferences can be used in MPLC phases. Several publications
described that patient preferences can be used in every phase of
the MPLC, from discovery until post marketing [3,29]. Here, we
describe the applications of patient preferences following the
structure of the MPLC (Fig. 1). An overview of the availability
of guidelines and frameworks on the use of patient preferences
throughout these phases is given in Table 1. Currently, the Inno-
vative Medicines Initiative (IMI) Patient Preferences in Benefit–
Risk Assessments during the Drug Life Cycle (PREFER) project is
working on providing recommendations on how patient prefer-
ences can inform decision making throughout the MPLC [9].
Discovery
Patient preferences are used in the discovery of new medical
products [30,31]. They can inform ideation and prototyping.
During ideation, the elicitation of patient preferences can help
Drug Discovery Today Volume 24, Number 1  January 2019 REVIEWS
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FIGURE 1
Applications of patient preferences along the medical product lifecycle (MPLC). Applications of patient preferences were mapped along the phases of the MPLC.
Applications were identified for all phases of the MPLC. Stages of the MPLC and their organization were identified as they emerged from the literature.
Abbreviations: HTA, Health Technology Assessment; PRO, patient-relevant outcomes; QALY, quality-adjusted life year.
TABLE 1
Availability of guidance on the use of patient preferences along the MPLCa
Phase of MPLC Availability of guidance Refs
Discovery Lack of guidance reported [98]
Preclinical development No guidance identified
Clinical development No guidance identified
Marketing authorization Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian
Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling:
Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. US Department of Health and
Human Services, FDA, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research
[4]
MDIC Patient-Centered Benefit–Risk Project Report: A Framework for Incorporating Information on Patient Preferences
regarding Benefit and Risk into Regulatory Assessments of New Medical Technology
[3]
ICH Harmonized Guideline: Revision of M4E Guideline on Enhancing the Format and Structure of Benefit-Risk
Information in ICH
[127]
HTA and reimbursement Kleme et al.: Patient perspective in health technology assessment of pharmaceuticals in Finland [107]
Kievit et al.: Taking patient heterogeneity and preferences into account in health technology assessments [20]
Lack of guidance reported [10,128]
Post marketing No guidance identified
a Abbreviations: ICH, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.
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care needs. For instance, this is demonstrated by the patient
preference study on fragile X syndrome (FXS) by Cross et al.
[32], described in the report of Selig [3,4,30]. Selig described
how stakeholders sought to get a better understanding of unmet
needs in FXS. Caregiver preferences were quantified for six treat-
ment outcomes. Caregivers found the ability of patients to control
their psychological, gestural, and verbal behavior to be the most
important treatment outcome. Cross et al. [32] stated that these
results would have the potential to inform future drug develop-
ment in FXS [30]. In addition to identifying unmet medical needs,
they can lead to a better understanding of the disease, personalexperiences of patients with the disease, and the acceptability of
benefits and risks [3,4,30,33]. Patient preferences can even be used
to inform the design of the target product profile, ensuring that
patient needs are met [34]. During prototyping, patient prefer-
ences can inform adaption of the design of the medical product
[3,4,11].
Preclinical development
Almost no evidence was found on applications of patient prefer-
ences in preclinical development. Patient preference were sug-
gested to ensure that the patient needs are addressed by the
medical product in design validation during preclinical testingwww.drugdiscoverytoday.com 59
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TABLE 2
Main US and European HTA bodies and payers interested in
patient preferencesa
Country Organization
Belgium Belgian Health Care Knowledge Centre (KCE)
England National Institute for Health and Care Excellence (NICE)
Finland Finnish Medicines Agency (Fimea)
France High Authority of Health (HAS)
Germany Institute for Quality and Efficiency in Health Care (IQWiG)
Scotland Scottish Medicines Consortium (SMC)
The Netherlands Care Institute Netherlands (CVZ)
USA Centers for Medicare & Medicaid Services (CMS)
a Based on Refs [19,29,61,62,65,66,78,81,129].
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patient preferences during preclinical development.
Clinical development
Patient preferences can be elicited during clinical development to
inform clinical trial design, product design validation, and benefit-
–risk assessment [3]. Patient preferences are currently taken into
account in clinical trial design [3,4,11,30], during which patient
preferences can be used to identify patient-relevant outcomes that
can inform the selection of clinical endpoints [4,22,35–37]. Also,
patient preferences can inform the development of reasonable
inclusion and exclusion criteria. Moreover, they can be used to
define experimental or control treatment arms in doubly random-
ized preference trial (DRPT) designs. In DRPT designs, the effect of
preferences on clinical outcomes can be analyzed [24,25,38–44].
Patient preferences can also be used in clinical trial designs to
calculate the acceptable level of uncertainty (significance level and
power) in clinical trials [45,46] and to inform development of
information that will be provided to patients during clinical trials,
including background information and study results [23].
Marketing authorization
Theuse of patient preferences in regulatorymarketing authorization
was discussed in 46 out of 113 (41%) publications. Regulatory
authorities such as the FDA [4] and the European Medicines Agency
(EMA) [1] are currently exploring the use of patient preferences [11–
13]. However, they do not require the submission of patient pre-
ferences [16]. The FDA accepts the submission of patient preference
information in approval applications for medical devices either as
supporting evidence or for informational purposes [4,47].
Patient preferences can be used at the marketing authorization
stage in benefit–risk assessment, assessment for early access [11],
and for optimizing labeling that will inform patients on benefits
and risks [3,4]. Use of patient preferences in benefit–risk assess-
ment has given rise to patient-centered benefit–risk (PCBR) assess-
ments [48,49]. Several initiatives are working on incorporating
patient preferences in benefit–risk assessments, such as the MDIC
Patient Centered Benefit-Risk Project, IMI PREFER, and the FDA’s
Center for Devices and Radiological Health (CDRH) Patient Pref-
erence Initiative [9,50]. In benefit–risk assessments, patient pre-
ferences can provide information on maximum acceptable risk,
minimum acceptable benefit, net clinical benefit, quality-adjusted
time without symptoms and toxicity, and relative value-adjusted
number needed to treat through multiple-criteria decision analy-
sis, benefit–less-risk analysis, the Gail assessment, and probabilistic
simulation methods [49,51–56]. These assessments are informed
by patient preferences through understanding the trade-offs that
patients make between benefits and risks [36]. Moreover, the
results of patient preference studies can not only show a range
of preferences, but also be used to identify subpopulations for
whom the benefits outweigh the risks [3,4,16,52,57]. Finally,
patient preferences can help to weigh the benefits and risks in
benefit–risk assessments based on the relative importance of out-
comes, benefits, and risks for the patients [51,58].
Health technology assessment & reimbursement
Although different publications described that patient preferences
can inform reimbursement decisions during the HTA and reim-60 www.drugdiscoverytoday.combursement stage [3,59–62], Dirksen et al. [63] reported that not
much evidence is available on the actual use of patient preferences
in reimbursement decision making and that multiple countries do
not consider patient preferences as an explicit prioritization crite-
rion. The use of patient preferences in HTA was discussed by 49 out
of 113 (43%) publications. Although cases have been described
where HTA bodies are reluctant towards considering patient pre-
ferences in their assessments, European and US HTA bodies and
payers have increasingly shown interest in using patient prefer-
ences in their assessments (Table 2) [2,8,10,11,31,64–67].
Twelve publications specifically mentioned the use of patient
preferences in economic evaluations, including cost-effectiveness,
cost–benefit, and cost–utility analyses [60,61,68–77]. In these
analyses, patient preferences can inform the identification of
patient-relevant outcomes, and the identification of subpopula-
tions for whom the benefits outweigh the risks [20,52,61,75]. In
addition, patient preferences can help to weigh outcomes accord-
ing to their relative importance to patients [20,61,75,78]. This
could be done by incorporating patient preferences and other
evidence into a multicriteria decision analysis [52,55]. Lastly,
Bewtra et al. [76] described that the utility values resulting from
patient preference studies can be used as quality-of-life weights in
the calculation of quality-adjusted life years (QALYs). QALYs and
EuroQol five dimensions (EQ-5D) utilities are frequently used in
HTA, but their classical use has been criticized by some, because
they only cover benefit for generic quality-of-life dimensions
rather than for all factors that important to patients [73,79,80].
Post marketing
Although some applications of patient preferences described
above might also be applicable to the postmarketing phase, some
additional postmarketing-specific applications were identified in
the MDIC report [3] and the FDA guidance [4]. During the post-
marketing phase, patient preferences could inform product accep-
tance by patients, extensions of indications, postmarketing
assessments through risk weighing, and product innovation [3,4].
Factors and situations influencing the value of patient
preference studies
Many factors and situations were identified that can influence the
value of patient preference studies (Fig. 2) [18,81]. Factors were
defined by the researchers as a fact or influence that occurs during
the organization, design, conduct, or communication of results of
the study and that contribute to, or affect, the value of results from
Drug Discovery Today Volume 24, Number 1  January 2019 REVIEWS
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FIGURE 2
Factors and situations influencing the value of patient preference studies. Factors and situations were mapped along the organization, design, conduct, and
communication and use of results of patient preference studies. Stages and steps of patient preference studies and their organization were identified as they
emerged from the literature. Abbreviations: MPLC, medical product lifecycle.
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stance or condition that occurs during the use of results and that
contributes to, or affects the value of, results from patient prefer-
ence studies. Situations were considered to be external to the
preference study and not controllable by the researcher. These
factors and situations are described below following the different
stages and steps of a patient preference study. Although there are
alternative ways to describe the stages of patient preference studies
and the different steps that they encompass, we identified steps
and their organization as they emerged from the literature, in
addition to the organizational context (see SP.III in the supple-
mental information online). Stages included study design, study
conduct, and communication and use of the results.
Organizational context
Multiple organizational factors were identified that determine the
value of patient preference studies, as discussed below.
Expertise
Clinical, medical product development, patient, methodological,
and statistical expertise of the conducting parties will have con-
siderable impact on whether and how a preference study is per-
formed [2,3,12,28,30,50,82,83]. Partnerships between industry,
academia, and patient organizations can be established to acquire
the needed expertise [28], but agreements on sharing and using the
data need to be established [28,30]. Expertise must be shared
between parties to ensure appropriate conduct by trained staff
and common understanding [4,28,30].
Patient centeredness
Patient centeredness of patient preference studies is an important
factor for success. The FDA guidance [4] states that the patientshould be ‘the central focus of the study’. Patients and patient
representatives can participate in the study design to guarantee
comprehensibility of the information and questions provided to
patients, to improve recruitment, and to ensure correct interpre-
tation and communication of results [4,16,28].
Good practices
Following good research practices, similar to Good Clinical Prac-
tices [84] and Good Pharmacoepidemiology Practices [85], will
ensure a correct design and conduct of the study and the value of
the results [30,86]. However, patient preference study-specific
guidance is often lacking (Table 3). Different initiatives are work-
ing on addressing methodological issues and providing recom-
mendations and guidance on the design and conduct of patient
preference studies (Table 4).
Ethics
Compliance with ethics requirements associated with questioning
patients is necessary in setting up a patient preference study, and
differentmeasureshavetobetakentomeettheseethics requirements
[14,60]. This process is time consuming. Obtaining ethics and/or
institutional review board (IRB) approval when questioning patients
can especially be challenging for industry, and will not always give
direct access to patients and their data [31,83]. Postmus et al. [16]
described that they did not collect demographic and clinical data in
their patient preference study to avoid the complexity of data pro-
tection, but stated that not having these data limited their analysis.
Financial resources
Conducting patient preference studies comes with a financial
burden that can differ among methods. Budgets of US$100 000–
400 000 (s90 000 to s370 000) have been quoted for quantitative
patient preference studies [2,3,12,30,31,50,82,83,87].www.drugdiscoverytoday.com 61
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TABLE 3
Availability of guidance on design and conduct of patient
preference studiesa
Topic Availability of guidance Refs
Good research practices ISPOR method-specific good
research practices
[4,78,103]
Choice of preference
exploration/elicitation method
Lack of guidance reported [3,18,98]
Selection of attributes Lack of guidance reported [3]
Whose preferences should be
measured
Lack of guidance reported [3,60]
Validity assessment Janssen et al.: Improving the
quality of discrete-choice
experiments in health: how can
we assess validity and reliability?
[109]
Lack of guidance reported [3]
a Abbreviations: ISPOR, International Society for Pharmacoeconomics and Outcomes
Research.
TABLE 4
Initiatives working on addressing methodological issues and
providing recommendations and guidance on the design and
conduct of patient preference studies
Initiative Website
IMI PREFER www.imi-prefer.eu
International Society for
Pharmacoeconomics and Outcomes
Research (ISPOR), Patient Preferences
Special Interest Group
www.ispor.org/sigs/
Stated-Preference-Methods.asp
International Academy of Health
Preference Research (IAHPR)
http://iahpr.org
International Health Economics Association
(iHEA), Health Preference Research Special
Interest Group
www.healtheconomics.org/
page/HealthPreference
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The conduct of a patient preference study is time-consuming,
ranging from 6 months to 2 years in complex cases
[2,12,30,82,83]. The recruitment of patients can particularly take
more time than is anticipated [82,83].
Timing along MPLC
It is not clear when patient preference studies should be conducted
because the submission of patient preferences is currently not
required by regulatory authorities and HTA bodies and/or payers,
but can be accepted as supporting evidence in a submission dossier
[3,4,50,55]. Currently, the study sponsor themselves needs to
decide whether information on patient preferences is needed
and to assess when and how to best collect it [3].
Patient preference study design
If patient preferences are elicited in well-designed and well-con-
ducted patient preference studies, patient preferences are consid-
ered to be valid scientific evidence that can be valuable in
informing decision making [4]. Thus, the design phase of a patient
preference study is a crucial phase. Inadequate design will nega-
tively influence the value of the study and make it unlikely that
outcomes will be considered by decision makers [12]. Design
factors that could influence the value of the study are discussed
below per step in the design process (Fig. 2).62 www.drugdiscoverytoday.comResearch question
The formulation of the research question will influence the value
of the study and choice of preference elicitation, or exploration
method, because the applicability of measuring patient prefer-
ences depends on the research question being asked [3,30]:
Patient versus other preferences
Decision making might not be sensitive to patient preferences
when preferences of other stakeholders, such as the general public
or clinicians, or other evidence, are found to be more important
than those of the patient [3]. This might be particularly important
when setting up a study to inform HTA because some reimburse-
ment decision-makers might wish to take the preferences of the
general public, as a healthcare payer, into account [55,63,88].
Sample definition
Besides obtaining ethics and/or IRB approval and access to patients
as described above, additional factors can influence the value of
patient preference studies during sample definition:
Clarity
Clearly defining the patient sample will ensure inclusion of the
right patients and value of results. Setting up inclusion and
exclusion criteria can safeguard a clear definition of the patient
sample [3].
Ensuring representativeness
Ensuring heterogeneity in the patient sample will result in gener-
alizable results that are representative of the preferences of the full
patient population for which the medical product is intended to be
launched [3,4,21,30,36,50,89,90]. Generalizability of the results
might be limited because of the eligibility criteria of the sample,
especially when patient preference studies are performed along-
side clinical trials [39,72,89,91–96].
Ability to participate
In the following patient populations, it might be more difficult to
measure preferences and it might be necessary to pay more attention
to the design of the exploration or elicitation instrument: (i) low
reading level or vision difficulties; (ii) not able to use a pencil or a
computer mouse; (iii) no access to the internet; (iv) physically
disabled; (v) cognitive impairments; and (vi) pediatric patient popu-
lations [3,4,70,83,97]. If preferences cannot be elicited directly from
patients themselves, preferences can be elicited from informal care-
givers, including parents and family members [3,4,33]. Parents can
be included to represent their children and family members to
represent older relatives [3,4,30,49,70,93,98]. However, their pre-
ferences might differ from those of the patients because they might
not assign the same values to various risks and benefits [4,99].
Sample size
During the design phase of patient preference studies, sample size
and power calculations can be made to allow for statistical analyses
later on [14,100]. If sample size calculations do not take heteroge-
neity into account, it might be impossible to do subpopulations
analysis when results are available [89,90,93,95,97]. Required
sample sizes differ among methods. For example, in general,
smaller samples are required for swing weighting compared with
DCEs [87].
Method selection
Many different types of preference exploration (qualitative) and
elicitation (quantitative) methods exist and can be used in patient
Drug Discovery Today Volume 24, Number 1  January 2019 REVIEWS
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patient preference studies are discussed below.
Match to research question
The optimal method for patient preference elicitation or explora-
tion will depend on the study objective and primary use of results,
and can be discussed with the stakeholders affected by, or evalu-
ating, the results in advance to increase the value of the study
[4,12,18,81,101]. Elicitation methods can quantify personal pre-
ferences, are structured, have clearly defined data types, have
limited response options, allow for statistical analysis, and are
recommended to be used when the aim is to explore preference
heterogeneity in different patient profiles [3,4,45,56]. Exploration
methods, such as interviews and focus groups, are recommended
for concept exploration and gaining in-depth knowledge of the
value of medical products [3,10,18]. Although it is important to
match the method to the research question, this specificity and
lack of standard measures is also what makes it hard to compare
preference studies across conditions, limiting their value for some
HTA agencies or reimbursement decision-makers [55].
Match to MPLC stage
The appropriate choice of the method depends on the phase in the
MPLC. During discovery, interactive exploration methods, such as
focus groups, have been described as being particularly useful [4].
In informing clinical trial design, both exploration and elicitation
methods have been used [24,25,35–37,39,102]. For benefit–risk
assessments, elicitation methods, such as DCE and AHP, as well as
exploration methods can be useful [12,53,59,103]. In HTA, elici-
tation methods that can examine willingness to pay are also
described as being useful [59,60,69,70,81,104,105]. However, until
now, HTA has mainly focused on patient involvement using
preference exploration methods [55,106,107].
Validity of the method
Given that participant responses might depend on the preference
elicitation method used [105,108], weights or values obtained
throughdifferentmethodsmightnotbecomparable [82]. Therefore,
guidance on which methods to use are of important to ensure the
value of patient preference studies in decision making. There is a lack
of guidance on how to assess the validity of a patient preference
study [3] (Box 5). However, work is underway onapproachesto assess
the validity of patient preference studies. For example, Janssen et al.
[109] created a conceptual model for the assessment of validity in
DCEs. The manner in which internal validity can be ensured or
assessed depends on the method used. Tervonen et al. [87] compared
swing weighting (SW) to DCEs and stated that internal validity is
automatically enforced with SW because of the exact nature of the
collected preferences, whereas the internal validity of DCE results
needs to be assessed manually. Assessment of external validity of
stated-preference methods, requiring a comparison between stated
and actual choices, is difficult to perform because of the use of
hypothetical choices [3,100].
Instrument design
Depending on the objective of a patient preference study, the
preference exploration or elicitation instrument can be designed
to explore or elicit preferences for health states, treatment attri-
butes, or treatment alternatives [81]. Different factors related to
the design of the instrument influence the value of the study, as
discussed below.Capturing demographics and clinical baseline data
Collecting demographic and clinical data is important if subgroup
analysis is planned to be performed [16].
Attribute development
Attributes could be identified through patient and caregiver in-
volvement, via a combination of literature reviews, interviews,
and meta-analyses of clinical data, and possibly via trial economic
evaluations [49,73,89,110]. Identifying attributes and their levels
that are relevant and do not overlap is necessary to produce results
that can be used to assess trade-offs [4,16,49]. When the real-life
attributes and levels are not sufficiently different and do overlap,
hypothetical choices can be included. This inclusion is often
mentioned as a limitation, because hypothetical choices can
reflect benefit and risk profiles other than of the actual therapies
that will be approved [3,36,91,93,96]. The number of attributes
that can be included in the instrument differs among methods. For
example, DCEs have been argued to not allow the inclusion of
many attributes and, thus, their applicability to contexts with
many attributes is limited [87].
Cognitive burden
Cognitive burden varies among methods, and minimization of this
burden will assure the value of the results [4,87]. In patient prefer-
ence elicitation studies, the cognitive burden for participants can be
high becauseof the useof hypothetical choicesand the largenumber
and representation of questions, attributes, and levels
[3,4,14,52,59,82,83,89,91,111]. Exploration methods, including
interviews and focus group discussions, have a low cognitive burden
for participants [61]. The patient population should be able to
perform the method-specific tasks and understand the questions
to realize results that can be used to assess meaningful trade-offs
[3,4,16,49,83,112]. Survey administration via interviews or work-
shops instead of online administration could provide support to
patients in understanding the questions [87,112].
Patient education
The extent to which patients are informed on the benefits and risks
of the medical product when participating in a patient preference
study is a determining factor for the value of the results [4,16].
Effective communication on benefits, risk, uncertainties, and
probabilities [30] can overcome cognitive burden [96] through
the use of appropriate numeric, verbal, and graphic representa-
tions [4,52,82]. Effective communication is especially important
when the instrument is designed on a self-administered basis
[4,30]. The amount of, and how, information is provided to
patients on the disease, risks, and benefits can influence their
preferences and the validity of the study
[24,30,63,83,98,110,11–115]. In describing outcomes to patients,
Hockley et al. [83] recommend defining the name of the outcome,
the description, recurrence, duration, and whether the outcome is
treatable. Although no further guidance on patient education in
patient preference studies was found, other sources that might
provide information on how to educate patients include the
guidance of the FDA on communicating benefits and risks
[116], the IMI EUPATI project [117], and the criteria for judging
the quality of patient decision aids from the International Patient
Decision Aid Standards (IPDAS) [118].
Question framing
When eliciting patient preferences, the framing of the questions
can influence preferences and the validity of the study [119,120].www.drugdiscoverytoday.com 63
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preferences for treatment are difficult to measure because of the
large influence of question framing and presentation effects (posi-
tive/negative question wording biases)’. In addition, Howard et al.
[120] demonstrated in a DCE study that attribute framing can
influence patient preferences.
Appeal of the instrument
The selection of a method and design of the instrument can
depend on how engaging the instrument is to prevent dropout.
Minimal dropout can be achieved when the instrument is engag-
ing through inclusion of engaging stimuli and exclusion of com-
plex formats and difficult to answer questions [3,83].
Patient preference study conduct
Relevant factors influencing the value of the study and related to
the study conduct are discussed below, based on each step of study
conduct (Fig. 2).
Participant recruitment
Besides obtaining ethics and/or IRB approval and access to
patients, as described above, another factor related to the recruit-
ment of participants that will influence the value of the study is
representativeness. Obtaining a representative sample of the pa-
tient population is a recruitment challenge for many patient
preference studies [2,100]. Sample bias can be caused by over-
inclusion of motivated patients, for example because of the re-
cruitment of patients via a sole patient organization
[16,36,49,78,93,121]. However, even in case of sample bias, the
results of patient preference studies might still be meaningful for
subpopulations [16].
Piloting and data collection
Testing validity and reliability
Performing pilot studies before the main data collection is done
will allow testing of validity and reliability of the preference
method and instrument [78,83].
Protocol compliance
During data collection, compliance with the protocol is a crucial
determinant of the validity and reliability of the results [4,30].
Analysis and interpretation
Robustness
When the robustness of the analysis is ensured, results of the
analysis will lead to appropriate interpretation [4,30]. However,
the value of the analysis can be reduced if the design of the study
was not well set up [82]. In quantitative patient preference studies,
statistical analysis can be performed, resulting in estimates and
uncertainties (confidence intervals or standard errors), which can
create a value model [4,16,33]. A sensitivity analysis can be per-
formed to assess the importance of the different values in the
model [4,33]. It might be necessary to use advanced regression
techniques in quantitative patient preference studies, such as the
mixed logit model [89,93]. For qualitative patient preference
studies, statistical analysis is not appropriate [92].
Preference heterogeneity
Given that individual preferences are measured in patient prefer-
ence studies, it is possible that there are differences between
patients in how they perceive and weigh the attributes64 www.drugdiscoverytoday.com[4,50,60,95,122]. Some patients might accept higher risks for a
certain benefit than other patients [3,4,50]. The detection of these
differences could not only reveal population-level preferences for
the medical product, but might also lead to the identification of
subpopulations tolerating the risks [3,4,50,52,62]. Using statistical
analysis tools that allow for detection of variation and distribution
of preferences, for example latent class analysis, makes subgroup
analysis possible [48,78,89,123]. However, the number of sub-
groups that can be evaluated is limited [48]. Allowing for the
identification of subpopulations for whom the benefits outweigh
the risks will increase the value of the study for benefit–risk
assessments and HTA [3,4,16,20,52,57].
Communication and use of the results from patient
preference studies
The results of patient preferences studies can be communicated to,
and used by, different stakeholders in decision making during the
MPLC. Besides the communication of results to stakeholders for
use in decision making, results can also be communicated back to
patients. However, the communication of results to patients
should be done in a different manner than communication to
assessors. During the use of the results, stakeholders’ attitudes
toward the use of patient preferences, but also clinical and market
situations can influence the value of patient preferences studies.
Factors arising in communication of results
Tailoring of communication
Results of patient preference studies can inform many stake-
holders, including industry, regulators, HTA bodies, payers, phy-
sicians, patient organizations, and patients. However, these
stakeholders have different needs and, therefore, tailoring of the
language, format, and venue of the study results to the stakeholder
group can enhance the value of the results to the stakeholders.
Patient organizations can participate in the communication of
results to patients to ensure comprehensibility of the disseminated
results [28].
Presentation of results
Visualizing results can prevent their misinterpretation, and can be
achieved through the use of tables, forest plots, and bar charts [82].
Situations influencing the value of patient preference studies
Patient population characteristics
Patient preferences might be especially useful in a population with
unmet medical needs or in rare diseases [3,4,49]. However, if the
medical product is developed for an unmet medical need with
severe symptoms and high mortality, or if the outcomes of treat-
ment with the medical product are more favorable than the out-
comes of the disease treated with best-available care, it might be
less valuable to elicit patient preferences [3].
Product characteristics
The characteristics of the investigational product and its alterna-
tives influence the value of patient preferences in decision making
[3,4,50]. Patient preferences can be useful for decision making
when: (i) it concerns a self-use medical product; (ii) there are
significant benefits and risks compared with alternatives; (iii) there
are different alternatives with different profiles (preference-sen-
sitive situations); (iv) the importance of the benefits and risks is
similar (uncertain benefit–risk profiles); (v) benefits and harms do
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disease area are used; (vii) risks can be identified for which no
benefit can compensate; and (viii) clinical experiences and end-
points are subjective [3,4,45,50,89,105,110]. When approval is
likely because of important benefits and nonsevere risks or because
of superiority compared with alternatives, patient preferences
might become less valuable [3].
Familiarity of assessors
Eliciting patient preferences might be especially valuable in pa-
tient populations with which regulators are not familiar [50].
When sponsors and regulators know the disease area and technol-
ogies well, patient preferences become less valuable [3]. In addi-
tion, the value of elicited quantitative patient preferences for
decision making can be limited by unfamiliarity with preference
methods among assessors interpreting the results [82,98].
Attitudes of assessors
There is no consensus on the role of patient preferences in decision
making along the MPLC. A consensus on this role might be
difficult to achieve because of distrust in the use of patient pre-
ferences resulting from the false impression that preferences can
only be used as averages, fear that patient preferences will replace
existing clinical evidence, barriers to ‘cultural change’, the lack of
consensus on the definition of patient preferences, and disap-
pointment risk (i.e., the possibility that patient preference studies
might yield unexpected results; e.g., some patients might not want
to accept the risks of a new product)
[1,3,4,12,30,31,36,47,50,63,64,66,70,81–83,98,124,125].
New competitors
If new treatment options become available, or if new benefits and
risks are identified, the results of previously performed patient
preference studies might no longer be valid and might need to be
reconducted [82].
Concluding remarks
Although limited evidence was found on the actual use of patient
preferences in decision making, they are gaining attention in
processes along the MPLC. We believe that additional guidance
on the use of patient preferences in assessments and decision
making is necessary to increase their use. Moreover, use of patient
preferences could increase if regulatory authorities, HTA bodies,
and payers would inform the industry about whether and how
they would use patient preferences in their processes, or would
state in what situations they find patient preferences valuable or
even require the submission of results from patient preference
studies.
Many factors and situations have to be taken into account when
designing and conducting a patient preference study to obtainvaluable results that can be used in assessments and decision
making. The main trends among the factors that we described
here that will contribute to the value of a patient preference study
are: (i) having a multidisciplinary team; (ii) ensuring patient
centeredness in the design as well as the conduct and communi-
cation of results; (iii) matching the sample and the method to the
research question; (iv) safeguarding validity in the method selec-
tion and instrument design; (v) reducing cognitive burden; (vi)
providing adequate patient education; (vii) guaranteeing that
preference heterogeneity can be measured and interpreted; and
(viii) tailoring communication of results to the audience. Further
research should focus on validating these results through the
exploration of stakeholder perspectives and by conducting patient
preference studies.
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